CMS Officially Recognizes NCCN Drugs & Biologics Compendium™
NCCN is pleased to announce that the Centers for Medicare and Medicaid Services (CMS) has recognized the NCCN Drugs & Biologics Compendium™ as a mandated reference for establishment of coverage policy and coverage decisions regarding the use of drugs and biologics in cancer care.
The NCCN Compendium will be used by CMS for national coverage determinations and by intermediaries and carriers for locoregional determinations. The major application will be in determinations about coverage for the use of drugs and biologics in oncology beyond the FDA approved indication.
This recognition comes on the heels of a recent announcement that UnitedHealthcare would base its coverage for chemotherapy drugs used in outpatient settings on the NCCN Drugs and Biologics Compendium™. Recognition from CMS, the nation’s largest health insurer, is another positive outcome of adapting and transcribing the recommendations from the NCCN Clinical Practice Guidelines in Oncology™ to a compendium format.
The NCCN Drugs & Biologics Compendium™ provides sound, scientific, evaluative information to the oncology community in order to inform and improve decision-making and outcomes.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. For more information, visit NCCN.org.
The NCCN Member Institutions are:
- Fred & Pamela Buffett Cancer Center
- Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
- City of Hope Comprehensive Cancer Center
- Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center
- Duke Cancer Institute
- Fox Chase Cancer Center
- Huntsman Cancer Institute at the University of Utah
- Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- Mayo Clinic Cancer Center
- Memorial Sloan Kettering Cancer Center
- Moffitt Cancer Center
- The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
- Roswell Park Cancer Institute
- Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
- St. Jude Children's Research Hospital/The University of Tennessee Health Science Center
- Stanford Cancer Institute
- University of Alabama at Birmingham Comprehensive Cancer Center
- UC San Diego Moores Cancer Center
- UCSF Helen Diller Family Comprehensive Cancer Center
- University of Colorado Cancer Center
- University of Michigan Comprehensive Cancer Center
- The University of Texas MD Anderson Cancer Center
- University of Wisconsin Carbone Cancer Center
- Vanderbilt-Ingram Cancer Center
- Yale Cancer Center/Smilow Cancer Hospital